Citigroup Maintains Buy on Zymeworks, Raises Price Target to $44

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $39 to $44.